dc.contributor.author | Rwegerera, Godfrey Mutashambara | |
dc.contributor.author | Rimbi, Munashe | |
dc.contributor.author | Mudhina, Vimbai | |
dc.contributor.author | Simone, Marang Tiny | |
dc.contributor.author | Sefo, Moranodi | |
dc.contributor.author | Segona, Bofelo | |
dc.date.accessioned | 2021-02-24T13:51:24Z | |
dc.date.available | 2021-02-24T13:51:24Z | |
dc.date.issued | 2019-09-24 | |
dc.identifier.citation | Rwegerera, G.M. et al. (2019) Dolutegravir induced sub-acute hepatic failure in HIV positive treatment naïve man in Botswana. Case reports in Internal Medicine, Vol. 6, No. 4, pp. 5-8 | en_US |
dc.identifier.issn | 2332-7251 | |
dc.identifier.uri | http://hdl.handle.net/10311/2043 | |
dc.description.abstract | Dolutegravir associated hepatic failure has rarely been reported. Hepatic failure can occur either acutely or after few weeks as it happened in our patient. We report a case of 61 years old HIV-positive treatment naïve patient who started experiencing features of hepatic injury one month after starting Dolutegravir-based regimen. Patient presented late with overt hepatic failure. We emphasize the importance of close monitoring both at initiation and long-term so as identify patients with early hepatic injury and limit fatal outcomes which are potentially avoidable. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sciedu Press, www.sciedupress.com | en_US |
dc.subject | Antiretroviral therapy | en_US |
dc.subject | Dolutegravir | en_US |
dc.subject | Hepatotoxicity | en_US |
dc.subject | Human Immunodeficiency Virus | en_US |
dc.title | Dolutegravir induced sub-acute hepatic failure in HIV positive treatment naïve man in Botswana | en_US |
dc.type | Published Article | en_US |
dc.link | http://www.sciedupress.com/journal/index.php/crim/article/view/15178/10166 | en_US |